Sleep problems in fragile X syndrome: Cross-sectional analysis of a large clinic-based cohort
- PMID: 34889523
- PMCID: PMC11057226
- DOI: 10.1002/ajmg.a.62601
Sleep problems in fragile X syndrome: Cross-sectional analysis of a large clinic-based cohort
Abstract
Fragile X syndrome (FXS), the leading cause of inherited intellectual disability and autism spectrum disorder, is associated with multiple neurobehavioral abnormalities including sleep difficulties. Nonetheless, frequency, severity, and consequences of sleep problems are still unclear. The Fragile X Online Registry with Accessible Research Database (FORWARD-version-3), including Clinician Report and Parent Report forms, was analyzed for frequency, severity, relationship with behavioral problems, and impact of sleep difficulties in a mainly pediatric cohort. A focused evaluation of sleep apnea was also conducted. Six surveyed sleep difficulties were moderately frequent (~23%-46%), relatively mild, affected predominantly younger males, and considered a problem for 7%-20% of families. Snoring was more prevalent in older individuals. All sleep difficulties were associated with irritability/aggression and most also to hyperactivity. Only severe snoring was correlated with sleep apnea (loud snoring: 30%; sleep apnea: 2%-3%). Sleep difficulties are prevalent in children with FXS and, although they tend to be mild, they are associated with behavioral problems and negative impact to families. Because of its cross-sectional nature, clinic-origin, use of ad hoc data collection forms, and lack of treatment data, the present study should be considered foundational for future research aiming at better recognition and management of sleep problems in FXS.
Keywords: fragile X syndrome; insomnia; problem behaviors; quality of life; sleep apnea.
© 2021 Wiley Periodicals LLC.
Conflict of interest statement
CONFLICTS OF INTEREST
Dejan B. Budimirovic has received funding from Seaside, Roche, Neuren, Pfizer, Shire, Lundbeck, Forest, Sunovion, SyneuRX, Alcobra, Akili, Medgenics, Purdue, Supernus as a main sub-investigator, and from Ovid and Zynerba Pharmaceuticals as a principal investigator on clinical trials. He also consulted on clinical trial outcome measures (Seaside, Ovid). All the above funding has been directed to Kennedy Krieger Institute/the Johns Hopkins Medical Institutions; DBB receives no personal funds and the Institute has no relevant financial interest in any of the commercial entities listed. Elizabeth Berry-Kravis has received funding from Acadia, Alcobra, AMO, Asuragen, BioMarin, Cydan, Fulcrum, GeneTx, GW, Ionis, Lumos, Marinus, Neuren, Neurotrope, Novartis, Ovid,Roche, Seaside Therapeutics, Ultragenyx, Vtesse/Sucampo/Mallinckrodt, Yamo, and Zynerba Pharmaceuticals to consult on clinical trial design, run clinical trials, or develop testing standards or biomarkers, all of which is directed to RUMC in support of rare disease programs; E.B.-K. receives no personal funds, and RUMC has no relevant financial interest in any of the commercial entities listed. Walter E. Kaufmann is Chief Medical Officer of Anavex Life Sciences Corp. He has been a consultant to AveXis, EryDel, GW, Marinus, Neuren, Newron, Ovid, Stalicla, and Zynerba. Currently, WEK does not receive personal funds and has no financial interest in any of these commercial entities. The other co-authors declare that they have no competing interests.
Figures
Similar articles
-
Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome.J Autism Dev Disord. 2024 Feb;54(2):725-737. doi: 10.1007/s10803-022-05821-7. Epub 2022 Nov 28. J Autism Dev Disord. 2024. PMID: 36441429
-
Autism Symptoms in Fragile X Syndrome.J Child Neurol. 2017 Sep;32(10):903-909. doi: 10.1177/0883073817712875. Epub 2017 Jun 15. J Child Neurol. 2017. PMID: 28617074 Review.
-
Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.Int J Mol Sci. 2017 Jun 20;18(6):1314. doi: 10.3390/ijms18061314. Int J Mol Sci. 2017. PMID: 28632163 Free PMC article. Review.
-
Screening for Fragile X Syndrome Among Filipino Children with Autism Spectrum Disorder.J Autism Dev Disord. 2023 Nov;53(11):4465-4473. doi: 10.1007/s10803-022-05707-8. Epub 2022 Aug 16. J Autism Dev Disord. 2023. PMID: 35972625
-
Double Genetic Hit: Fragile X Syndrome and Partial Deletion of Protein Patched Homolog 1 Antisense as Cause of Severe Autism Spectrum Disorder.J Dev Behav Pediatr. 2020 Dec;41(9):724-728. doi: 10.1097/DBP.0000000000000850. J Dev Behav Pediatr. 2020. PMID: 32947579
Cited by
-
Exploring an objective measure of overactivity in children with rare genetic syndromes.J Neurodev Disord. 2024 Apr 18;16(1):18. doi: 10.1186/s11689-024-09535-y. J Neurodev Disord. 2024. PMID: 38637764 Free PMC article.
-
State-of-the-art therapies for fragile X syndrome.Dev Med Child Neurol. 2024 Jul;66(7):863-871. doi: 10.1111/dmcn.15885. Epub 2024 Feb 22. Dev Med Child Neurol. 2024. PMID: 38385885 Review.
-
Ketogenic Diet Affects Sleep Architecture in C57BL/6J Wild Type and Fragile X Mice.Int J Mol Sci. 2023 Sep 22;24(19):14460. doi: 10.3390/ijms241914460. Int J Mol Sci. 2023. PMID: 37833907 Free PMC article.
-
Drosophila melanogaster as a Model to Study Fragile X-Associated Disorders.Genes (Basel). 2022 Dec 28;14(1):87. doi: 10.3390/genes14010087. Genes (Basel). 2022. PMID: 36672829 Free PMC article. Review.
-
Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome.J Autism Dev Disord. 2024 Feb;54(2):725-737. doi: 10.1007/s10803-022-05821-7. Epub 2022 Nov 28. J Autism Dev Disord. 2024. PMID: 36441429
References
-
- Budimirovic B, Haas-Givler B, Blitz R, Esler A, Kaufmann W, Sudhalter V, … Berry-Kravis E (2014. (updated 2020)). Understanding autism spectrum disorders in fragile X syndrome. Retrieved from https://fragilex.org/our-research/treatment-recommendations/understandin...
-
- Budimirovic B, Schlageter A, Filipovic-Sadic S, Protic DD, Bram E, Mahone EM, … Latham GJ (2020). A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments. Brain Sci, 10(10). doi:10.3390/brainsci10100694 - DOI - PMC - PubMed